

Raymond L Comenzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5389567/publications.pdf>

Version: 2024-02-01

230
papers

9,962
citations

76031

42
h-index

42259

96
g-index

233
all docs

233
docs citations

233
times ranked

7462
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized phase 3 study of ixazomib+dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. <i>Leukemia</i> , 2022, 36, 225-235.	3.3	29
2	Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 656-669.	1.0	7
3	Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy. <i>Annals of Hematology</i> , 2022, 101, 369-378.	0.8	8
4	Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. , 2022, 13, 12.		2
5	Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	0.6	1
6	Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone±daratumumab: Results from the ANDROMEDA study. <i>American Journal of Hematology</i> , 2022, 97, 719-730.	2.0	3
7	Laboratory-Based Rationale for Targeting the Protein Homeostasis Network in AL Amyloidosis. <i>Hemato</i> , 2022, 3, 298-317.	0.2	0
8	Immunotherapy in AL Amyloidosis. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1059-1071.	1.3	3
9	The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. <i>Blood Reviews</i> , 2021, 45, 100720.	2.8	15
10	Involved free light chains $\leq 10\text{ mg/L}$ with treatment predict better outcomes in systemic light-chain amyloidosis. <i>American Journal of Hematology</i> , 2021, 96, E20-E23.	2.0	4
11	Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis. <i>Journal of Clinical Neuroscience</i> , 2021, 84, 33-37.	0.8	15
12	Implementing structured handoffs to verify operating room blood delivery using a quality academy training program: an interrupted time-series analysis. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	0.9	0
13	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 701-710.	0.2	4
14	Smoldering multiple myeloma – Past, present, and future. <i>Blood Reviews</i> , 2021, , 100869.	2.8	2
15	Association between spinal stenosis and wild-type ATTR amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 226-233.	1.4	23
16	Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. <i>Clinical Neurology and Neurosurgery</i> , 2021, 206, 106708.	0.6	10
17	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	13.9	268
18	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	2.8	53

#	ARTICLE	IF	CITATIONS
19	OUP accepted manuscript. <i>Clinical Chemistry</i> , 2021, 67, 1588-1589.	1.5	0
20	AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies. <i>JACC: CardioOncology</i> , 2021, 3, 467-487.	1.7	31
21	OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S22.	0.2	2
22	Risk Factors for Early Sudden Cardiac Death in Patients with Systemic Light-Chain Amyloidosis on Treatment. <i>Blood</i> , 2021, 138, 3756-3756.	0.6	1
23	The Pattern of Organ Responses Varies in Patients with Systemic Light-Chain Amyloidosis and Heart or Kidney or Heart and Kidney Involvement Who Achieve Deep Hematologic Responses. <i>Blood</i> , 2021, 138, 2715-2715.	0.6	0
24	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. <i>Blood</i> , 2021, 138, 4771-4771.	0.6	0
25	Belantamab Mafadotin in Patients with Relapsed/Refractory AL Amyloidosis with Myeloma. <i>Blood</i> , 2021, 138, 1670-1670.	0.6	3
26	Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. <i>Blood</i> , 2021, 138, 159-159.	0.6	5
27	Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 184-189.	0.2	15
28	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	1.2	8
29	Shedding Tears to Clear the Way. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, xiii-xiv.	0.9	0
30	How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e826-e831.	0.2	5
31	Liver and Gastrointestinal Involvement. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1081-1090.	0.9	4
32	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. <i>BMC Family Practice</i> , 2020, 21, 198.	2.9	60
33	<p>Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7891-7903.	0.9	32
34	Febrile Neutropenia and Bacteremia after High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients Treated Inpatient Versus Outpatient. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S47-S48.	2.0	0
35	Wild-Type Transthyretin Amyloidosis Occurring in the Ligamentum Flavum of the Cervicothoracic Spine. <i>World Neurosurgery</i> , 2020, 142, e325-e330.	0.7	11
36	Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1455-1462.	0.8	31

#	ARTICLE	IF	CITATIONS
37	Implementation and impact of a multidisciplinary coagulation factor stewardship program at an academic medical center. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 715-717.	1.0	4
38	Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e137-e143.	0.2	12
39	Presence of soluble and cell surface cell maturation antigen in systemic light chain amyloidosis and its modulation by gamma secretase inhibition. <i>American Journal of Hematology</i> , 2020, 95, E110-E113.	2.0	10
40	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , 2020, 136, 48-50.	0.6	11
41	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 44-45.	0.6	5
42	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 6-7.	0.6	5
43	Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis. <i>Blood</i> , 2020, 136, 23-24.	0.6	1
44	Daratumumab plus CyBORd for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <i>Blood</i> , 2020, 136, 71-80.	0.6	146
45	Outcomes of Patients with Multiple Myeloma Harboring Gain/Amplification 1q in the Era of Modern Therapy. <i>Blood</i> , 2020, 136, 45-46.	0.6	0
46	Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience. <i>Blood</i> , 2020, 136, 16-17.	0.6	0
47	Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. <i>Blood</i> , 2020, 136, 11-11.	0.6	3
48	Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience. <i>Blood</i> , 2020, 136, 44-45.	0.6	1
49	High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. <i>Bone Marrow Transplantation</i> , 2019, 54, 508-518.	1.3	17
50	Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 686-688.	0.2	16
51	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
52	A case report "renal heavy chain amyloidosis and T-cell large granular lymphocytic leukaemia. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 130-131.	1.4	1
53	Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 113-114.	1.4	2
54	Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac Tissue with Bilateral Carpal Tunnel Syndrome. <i>World Neurosurgery</i> , 2019, 131, 104-107.	0.7	10

#	ARTICLE	IF	CITATIONS
55	Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fc γ 3 receptor 3A V158F polymorphisms. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
56	Use of novel therapies in the treatment of light chain amyloidosis. <i>Blood Reviews</i> , 2019, 37, 100581.	2.8	12
57	A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases. <i>Gene Therapy</i> , 2019, 26, 187-197.	2.3	7
58	A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis. <i>American Journal of Case Reports</i> , 2019, 20, 43-47.	0.3	6
59	Stigmata of amyloidosis; external manifestations of internal disease. <i>British Journal of Haematology</i> , 2019, 186, 10-10.	1.2	1
60	Preliminary evidence of efficacy of venetoclax in relapsed and refractory AL amyloidosis.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e327-e328.	0.2	4
61	Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission But With Persistent Renal Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e335-e336.	0.2	0
62	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). <i>Blood</i> , 2019, 134, 139-139.	0.6	34
63	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. <i>Blood</i> , 2019, 134, 3166-3166.	0.6	27
64	B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition. <i>Blood</i> , 2019, 134, 4409-4409.	0.6	5
65	In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels \leq 10mg/L Are Associated with Optimal Long-Term Survival. <i>Blood</i> , 2019, 134, 4369-4369.	0.6	8
66	Monoclonal Gammopathies and Their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease. <i>Blood</i> , 2019, 134, 5498-5498.	0.6	0
67	Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease. <i>Blood</i> , 2019, 134, 5500-5500.	0.6	0
68	Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response. <i>Blood</i> , 2019, 134, 5502-5502.	0.6	0
69	Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 161-167.	0.6	17
70	Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. <i>Experimental Hematology and Oncology</i> , 2018, 7, 27.	2.0	15
71	Beyond NEOD001 for systemic light-chain amyloidosis. <i>Blood</i> , 2018, 132, 1992-1993.	0.6	18
72	Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 156-159.	1.4	12

#	ARTICLE	IF	CITATIONS
73	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e493-e499.	0.2	20
74	Seeking AL Amyloidosis Very Early: The SAVE Trial – Identifying Clonal Lambda Light Chain Genes in Patients with MGUS or Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 1903-1903.	0.6	4
75	Effective Lipidoid Nanoparticle Delivery In Vivo of siRNA Targeting Kappa Light Chain Production in a Murine Xenograft Model. <i>Blood</i> , 2018, 132, 3208-3208.	0.6	2
76	Identifying a Murine Xenograft Model Relevant to Light-Chain Specific Approaches to Human Ig Light-Chain Diseases. <i>Blood</i> , 2018, 132, 5611-5611.	0.6	0
77	Senescent CD8+ T Cells in Myeloma Patients: Implications for Cellular Therapies. <i>Blood</i> , 2018, 132, 5688-5688.	0.6	1
78	Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center. <i>Cancer Treatment and Research Communications</i> , 2017, 11, 1-5.	0.7	0
79	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. <i>Blood</i> , 2017, 130, 974-981.	0.6	391
80	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. <i>Blood</i> , 2017, 130, 597-605.	0.6	108
81	Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. <i>Circulation</i> , 2017, 135, 1357-1377.	1.6	319
82	NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 825.	1.2	0
83	Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e97-e98.	0.2	0
84	Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 759-766.	0.2	11
85	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
86	Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. <i>Bone Marrow Research</i> , 2016, 2016, 1-6.	1.7	3
87	SP051NEOD001 DEMONSTRATES RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT RENAL DYSFUNCTION. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i103-i103.	0.4	0
88	Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. <i>Blood</i> , 2016, 127, 2275-2280.	0.6	21
89	NEOD001 Demonstrates Cardiac Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction in a Phase 1/2 Study Expansion. <i>Journal of Cardiac Failure</i> , 2016, 22, S64.	0.7	0
90	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. <i>Journal of Clinical Oncology</i> , 2016, 34, 1097-1103.	0.8	176

#	ARTICLE	IF	CITATIONS
91	Impact of Cardiac Stage and Hematologic Response on AL Amyloidosis Patients with Renal Involvement. <i>Blood</i> , 2016, 128, 2136-2136.	0.6	1
92	Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 4523-4523.	0.6	1
93	The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction. <i>Blood</i> , 2016, 128, 5690-5690.	0.6	5
94	Risk-Adapted Melphalan and Stem Cell Transplantation after Suboptimal Responses to Bortezomib-Based Initial Therapy in Patients with Systemic Light-Chain Amyloidosis (AL). <i>Blood</i> , 2016, 128, 5831-5831.	0.6	1
95	NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 644-644.	0.6	9
96	Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 645-645.	0.6	46
97	Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response. <i>Blood</i> , 2016, 128, 647-647.	0.6	1
98	The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8073-TPS8073.	0.8	2
99	A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, yttrium-90) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Stem Cell Transplant (ASCT) for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S199.	2.0	3
100	Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. <i>Advances in Therapy</i> , 2015, 32, 920-928.	1.3	187
101	Extracorporeal Photophoresis in Reduced Intensity Conditioning: 14 Year Follow-up of 206 Patients Reveals an Efficacious Regimen with Low Rates of GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S35-S36.	2.0	0
102	Three-dimensional Speckle Tracking Echocardiography in Light Chain Cardiac Amyloidosis: Examination of Left and Right Ventricular Myocardial Mechanics Parameters. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 657-664.	0.4	13
103	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Resultsâ€“Medicare Database. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1823-1829.	2.0	30
104	CD38 Monoclonal Antibody Therapies for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 635-645.	0.2	25
105	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
106	Out, Out â€” Making Amyloidâ€™s Candle Briefer. <i>New England Journal of Medicine</i> , 2015, 373, 1167-1169.	13.9	14
107	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	0.8	163
108	The Majority of Patients with Relapsing Light Chain (AL) Amyloidosis Are Not Eligible for Enrollment Onto Clinical Trials: Using Screen Failures to Define Major Unmet Medical Needs. <i>Blood</i> , 2015, 126, 1786-1786.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2015, 126, 3041-3041.	0.6	2
110	Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials. <i>Blood</i> , 2015, 126, 1975-1975.	0.6	0
111	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. <i>Blood</i> , 2015, 126, 3049-3049.	0.6	0
112	Colchicine Can be an Effective Adjunctive Treatment for Extensive Refractory Chronic-Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 5461-5461.	0.6	0
113	Improvements in Patient Outcomes with Autologous Stem Cell Transplantation for Multiple Myeloma over 25 Years at a Single Center. <i>Blood</i> , 2015, 126, 5496-5496.	0.6	0
114	How we treat systemic light-chain amyloidosis. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 315-24.	0.3	8
115	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). <i>Haematologica</i> , 2014, 99, 1479-1485.	1.7	118
116	Immunoglobulin light chain amyloidosis. <i>Expert Review of Hematology</i> , 2014, 7, 143-156.	1.0	98
117	Plasma Cell Neoplasms, Their Precursor States, and Their Prediction of Organ Damage. <i>Journal of Clinical Oncology</i> , 2014, 32, 2679-2682.	0.8	8
118	Twists and turns of determining amyloid type and amyloid-related organ damage: discordance and clinical skepticism in the era of proteomic typing. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 62-65.	1.4	4
119	Improvement of Blood Glucose Control on the Bone Marrow Transplant (BMT) Unit: A Retrospective Review of Our Quality Improvement Pilot Program. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S202.	2.0	0
120	Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 380-388.	0.2	38
121	LECT2 makes the amyloid list. <i>Blood</i> , 2014, 123, 1436-1437.	0.6	9
122	One siRNA pool targeting the 5' constant region stops 5' light-chain production and causes terminal endoplasmic reticulum stress. <i>Blood</i> , 2014, 123, 3440-3451.	0.6	34
123	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. <i>Blood</i> , 2014, 124, 2498-2506.	0.6	62
124	An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 176-176.	0.6	27
125	Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2014, 124, 3170-3170.	0.6	4
126	Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). <i>Blood</i> , 2014, 124, 3450-3450.	0.6	21

#	ARTICLE	IF	CITATIONS
127	Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2014, 124, 3480-3480.	0.6	5
128	Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone Induction. <i>Blood</i> , 2014, 124, 3991-3991.	0.6	11
129	A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2014, 124, 4741-4741.	0.6	15
130	siRNA for the Ig Light Chain Constant Region Reduces Light Chain Production and Secretion By Human Plasma Cells and in a Murine Xenograft Model. <i>Blood</i> , 2014, 124, 5722-5722.	0.6	1
131	Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 5924-5924.	0.6	0
132	Increased Bone Marrow Plasma Cells at Diagnosis Predicts Overall Mortality in AL Amyloidosis Patients Undergoing Risk-Adapted Stem Cell Transplant. <i>Blood</i> , 2014, 124, 2522-2522.	0.6	0
133	Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists. <i>Blood</i> , 2014, 124, 2595-2595.	0.6	0
134	New Insights and Modern Treatment of AL Amyloidosis. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 291-298.	1.2	21
135	Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients. <i>Clinical Therapeutics</i> , 2013, 35, 1614-1620.	1.1	18
136	Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S131-S132.	2.0	0
137	Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 8545-8545.	0.8	0
138	Plerixafor and G-CSF For Autologous Stem Cell Mobilization In AL Amyloidosis: A Single Center Experience. <i>Blood</i> , 2013, 122, 4516-4516.	0.6	0
139	A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 4830-4840.	3.2	128
140	The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of <i>p53</i> -Mutated Multiple Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1781-1788.	1.9	52
141	Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with International Staging System stage II or III, or extramedullary disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 275-281.	0.6	13
142	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549.	0.8	735
143	Clinical and Echocardiographic Correlates of Elevated Troponin in Amyloid Light-Chain Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2012, 110, 1180-1184.	0.7	21
144	Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 49-58.	0.2	28

#	ARTICLE	IF	CITATIONS
145	The Challenge of Systemic Immunoglobulin Light-Chain Amyloidosis (AL). <i>Sub-Cellular Biochemistry</i> , 2012, 65, 609-642.	1.0	22
146	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. <i>Leukemia</i> , 2012, 26, 2317-2325.	3.3	332
147	Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity.. <i>Blood</i> , 2012, 120, 2968-2968.	0.6	5
148	Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience.. <i>Blood</i> , 2012, 120, 3109-3109.	0.6	2
149	Long-Term Outcomes of Patients with Systemic Light Chain Amyloidosis (AL) Treated At Diagnosis with Risk-Adapted Stem Cell Transplant and Consolidation with Novel Agents.. <i>Blood</i> , 2012, 120, 3150-3150.	0.6	5
150	A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma. <i>Blood</i> , 2012, 120, 4029-4029.	0.6	12
151	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. <i>Blood</i> , 2012, 120, 731-731.	0.6	12
152	Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 1863-1863.	0.6	1
153	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	5.1	263
154	Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. <i>Blood</i> , 2011, 118, 865-873.	0.6	161
155	Urinary Excretion of Epinephrine and Dopamine Correlates with Efficiency of G-CSF Mobilized Stem Cells in Patients with AL Amyloidosis. <i>Blood</i> , 2011, 118, 316-316.	0.6	2
156	Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis. <i>Blood</i> , 2011, 118, 5139-5139.	0.6	1
157	Proteasome Activity As a Biomarker in Multiple Myeloma (MM): In MM Cells Treated with Bortezomib (BTZ) or Epoxomicin (EPX) Caspase 3/7 Activation Is Inversely Related to Baseline β ² 1 and β ² 5 Activity. <i>Blood</i> , 2011, 118, 1431-1431.	0.6	0
158	Proteasome Activity Not M-Protein Production Influences Multiple Myeloma (MM) Responsiveness to Bortezomib (BZB): The Key Role of PSMB5,. <i>Blood</i> , 2011, 118, 3491-3491.	0.6	0
159	Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients \geq 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,. <i>Blood</i> , 2011, 118, 4153-4153.	0.6	0
160	Who knows how to treat systemic light chain amyloidosis?. <i>Oncology</i> , 2011, 25, 626, 628-9, 632-3.	0.4	1
161	Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 287-294.	0.9	85
162	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	0.8	358

#	ARTICLE	IF	CITATIONS
163	Plerixafor (Mozobil®) Alone to Mobilize Hematopoietic Stem Cells from Multiple Myeloma Patients for Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 695-700.	2.0	32
164	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. <i>Blood</i> , 2010, 116, 1364-1364.	0.6	19
165	Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy. <i>Blood</i> , 2010, 116, 2391-2391.	0.6	4
166	Coincidental Gammopathies In Patients with Systemic Amyloidosis and Transthyretin Gene Mutations. <i>Blood</i> , 2010, 116, 2948-2948.	0.6	3
167	Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. <i>Blood</i> . 2010. 116. 41-41.	0.6	14
168	Cancer-Testis (CT) Antigen Expression In AL Amyloidosis. <i>Blood</i> , 2010, 116, 4055-4055.	0.6	0
169	Cyclin D1 Overexpression In Clonal Plasma Cells In Systemic AL Amyloidosis Is Associated with Differential Expression of Protein Quality Control Genes and Bias In Clonal Germline IgVL donor Gene Use. <i>Blood</i> , 2010, 116, 4043-4043.	0.6	0
170	Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study. <i>Blood</i> , 2010, 116, 4299-4299.	0.6	0
171	Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2010, 116, 1353-1353.	0.6	0
172	Frequencies and Types of Arrhythmias in Patients With Systemic Light-Chain Amyloidosis With Cardiac Involvement Undergoing Stem Cell Transplantation on Telemetry Monitoring. <i>American Journal of Cardiology</i> , 2009, 104, 990-994.	0.7	52
173	AL amyloidosis and progression to multiple myeloma with gain(1q). <i>British Journal of Haematology</i> , 2009, 144, 963-964.	1.2	9
174	How I treat amyloidosis. <i>Blood</i> , 2009, 114, 3147-3157.	0.6	80
175	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. <i>Blood</i> , 2009, 114, 1489-1497.	0.6	153
176	Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.. <i>Blood</i> , 2009, 114, 533-533.	0.6	4
177	Elevated Cyclin D1 (CCND1) Expression in the Plasma Cells of Patients with Systemic AL Amyloidosis at Diagnosis Is Associated with Higher Brain Natriuretic Peptide (BNP) Levels, Increased Plasma Cells and Significantly Poorer Survival.. <i>Blood</i> , 2009, 114, 2815-2815.	0.6	1
178	Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.. <i>Blood</i> , 2009, 114, 1865-1865.	0.6	0
179	Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 6-11.	2.0	22
180	Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. <i>Blood</i> , 2008, 111, 549-557.	0.6	24

#	ARTICLE	IF	CITATIONS
181	CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. <i>Blood</i> , 2008, 111, 3403-3406.	0.6	37
182	Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.. <i>Blood</i> , 2008, 112, 3329-3329.	0.6	2
183	MAGE-A3 or NY-ESO1 Expression and Spontaneous Antibody Responses to NY-ESO1 in Newly Diagnosed Multiple Myeloma Patients Are Associated with Worse Overall Survival. <i>Blood</i> , 2008, 112, 5110-5110.	0.6	0
184	CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 842-842.	0.6	0
185	Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response. <i>Blood</i> , 2008, 112, 3712-3712.	0.6	2
186	Managing Systemic Light-Chain Amyloidosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 179-187.	2.3	41
187	Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone and thalidomide for systemic light-chain amyloidosis: results of a phase II trial. <i>British Journal of Haematology</i> , 2007, 139, 224-233.	1.2	112
188	Predictors of Survival in De Novo Cardiac Amyloidosis.. <i>Blood</i> , 2007, 110, 2870-2870.	0.6	1
189	High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.. <i>Blood</i> , 2007, 110, 5113-5113.	0.6	0
190	Systemic Immunoglobulin Light-Chain Amyloidosis. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 182-185.	1.4	19
191	Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. <i>Blood</i> , 2006, 107, 3489-3491.	0.6	144
192	Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. <i>British Journal of Haematology</i> , 2006, 132, 155-161.	1.2	39
193	Pyridone 6, A Pan-Janus Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells. <i>Cancer Research</i> , 2006, 66, 9714-9721.	0.4	145
194	Increased Calreticulin Expression in Clonal Plasma Cells Is Associated with Complete Response to Melphalan and Autologous Stem Cell Transplant in Systemic Light-Chain Amyloidosis.. <i>Blood</i> , 2006, 108, 3096-3096.	0.6	2
195	Single Agent AMD3100 Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation in Patients with Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 3381-3381.	0.6	0
196	Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.. <i>Blood</i> , 2006, 108, 3087-3087.	0.6	0
197	CD32B on Clonal Plasma Cells in Systemic Light-Chain Amyloidosis (AL) and Multiple Myeloma (MM): A Target for Immunotherapy in Both Disorders and a Prognostic Marker in MM.. <i>Blood</i> , 2006, 108, 3489-3489.	0.6	0
198	Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. <i>British Journal of Haematology</i> , 2005, 128, 636-644.	1.2	62

#	ARTICLE	IF	CITATIONS
199	Adjuvant Dexamethasone (D) ± Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).. Blood, 2005, 106, 1163-1163.	0.6	3
200	The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.. Blood, 2005, 106, 3481-3481.	0.6	1
201	Plasma Cell Gene-Expression Profiles in Patients with Systemic AL Amyloidosis: Responses to Melphalan and Stem Cell Transplant Are Associated with Differential Expression of Genes Involved in Translation, Protein Degradation and Detoxification.. Blood, 2005, 106, 3405-3405.	0.6	5
202	Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.. Blood, 2005, 106, 1156-1156.	0.6	0
203	The Abdominal Fat Pad Aspirate for Diagnosing Amyloidosis Is a Useful Tool.. Blood, 2005, 106, 5107-5107.	0.6	0
204	Seeking Diagnostic Confidence in Typing Amyloidosis: Prospective Results with an Algorithm To Minimize Misdiagnosis of Immunoglobulin Light-Chain (AL) Amyloidosis.. Blood, 2005, 106, 5099-5099.	0.6	0
205	Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.. Blood, 2004, 104, 2409-2409.	0.6	2
206	Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.. Blood, 2004, 104, 5113-5113.	0.6	0
207	Risk-Adapted Intravenous Melphalan Followed by Adjuvant Dexamethasone (D) and Thalidomide (T) for Newly Diagnosed Patients with Systemic AL Amyloidosis (AL): Interim Results of a Phase II Study.. Blood, 2004, 104, 542-542.	0.6	0
208	Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy. Journal of Neuro-Oncology, 2003, 63, 207-211.	1.4	12
209	Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. British Journal of Haematology, 2003, 122, 728-744.	1.2	59
210	Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood, 2003, 102, 477-479.	0.6	22
211	Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood, 2003, 102, 4369-4376.	0.6	116
212	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-98.	2.0	86
213	Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 2002, 99, 4276-4282.	0.6	335
214	The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden. Blood, 2001, 98, 714-720.	0.6	251
215	Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma. New England Journal of Medicine, 2001, 344, 1951-1952.	13.9	213
216	Primary systemic amyloidosis. Current Treatment Options in Oncology, 2000, 1, 83-89.	1.3	34

#	ARTICLE	IF	CITATIONS
217	Hematopoietic Cell Transplantation for Primary Systemic Amyloidosis: What Have We Learned. <i>Leukemia and Lymphoma</i> , 2000, 37, 245-258.	0.6	33
218	Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 126-132.	1.4	7
219	Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. <i>British Journal of Haematology</i> , 1999, 104, 553-559.	1.2	68
220	Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. <i>British Journal of Haematology</i> , 1999, 106, 744-751.	1.2	79
221	Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. <i>Blood</i> , 1998, 91, 3662-3670.	0.6	323
222	The Systemic Amyloidoses. <i>New England Journal of Medicine</i> , 1997, 337, 898-909.	13.9	1,135
223	Advances in the Treatment of Plasma Cell Diseases. <i>Hospital Practice (1995)</i> , 1996, 31, 67-88.	0.5	6
224	Anomalous ABO Phenotype in a Child after an ABO-Incompatible Liver Transplantation. <i>New England Journal of Medicine</i> , 1992, 326, 867-870.	13.9	42
225	Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. <i>Journal of Pediatrics</i> , 1992, 120, 926-928.	0.9	88
226	Clinical correlation of positive direct antiglobulin tests in patients with sickle cell disease. <i>Immunohematology</i> , 1992, 8, 13-16.	0.2	1
227	Prompt engraftment using autologous peripheral blood stem cells for double autologous bone marrow rescue. <i>American Journal of Hematology</i> , 1991, 36, 152-153.	2.0	5
228	A glycosaminoglycan inhibitor of thrombin: A new mechanism for abnormal hemostatic assays in cancer. <i>American Journal of Hematology</i> , 1991, 38, 24-29.	2.0	10
229	Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis. , 0, , 914-930.		0
230	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	0.6	1